Overview

Prophylaxis Roles of IL-2 Treatment on GVHD After Transplantation

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The effects of haploidentical rhG-CSF-mobilized unmanipulated blood and marrow transplantation (HBMT) on hematological malignancies are well established.The aim of this prospective cohort trial is to determine if acute graft-versus-host disease (aGVHD) could be decreased with IL2 therapy post HBMT.
Phase:
Phase 2
Details
Lead Sponsor:
Peking University People's Hospital
Treatments:
Interleukin-2